Esperion's ETC-1002 succeeds in Phase IIb, but Zetia combo could be key
This article was originally published in Scrip
Esperion Therapeutics jumped 33.2% to $32.52 per share after the stock market closed on 1 October when the company revealed statistically significant reductions in LDL cholesterol for its lead drug candidate ETC-1002 versus the Merck & Co blockbuster Zetia (ezetimibe).
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.